Breaking NEJM Research: Key Insights from Ahead-of-Print Findings
Chronic hepatitis B virus (HBV) infection remains a global health crisis, affecting over 250 million people worldwide and causing an estimated 820,000 annual deaths from cirrhosis and hepatocellular carcinoma. For decades, standard-of-care therapies like nucleos(t)ide analogs (NAs) have suppressed viral replication but failed to achieve functional cures—defined as sustained loss of hepatitis B surface antigen (HBsAg). Now, phase 3 results for bepirovirsen, an investigational antisense oligonucleotide targeting the HBV pregenomic RNA, offer a glimmer of hope. Published ahead of print in The New England Journal of Medicine, the study reveals a 20% HBsAg loss rate at 48 weeks—double the historical benchmark for NAs. Yet questions linger: Will this translate to durable remission? And how will clinicians integrate it into existing treatment paradigms?
Key Clinical Takeaways:
- Bepirovirsen achieves functional cures in 1 in 5 patients—a landmark efficacy rate for HBV therapy, though sustained responses beyond 48 weeks remain unproven.
- Injection-site reactions and flu-like symptoms are the primary adverse events, with no new safety signals compared to placebo.
- Phase 3 data suggest potential for combination therapy with NAs, but regulatory approval hinges on long-term follow-up and real-world efficacy.
How Bepirovirsen Disrupts the Pathogenesis of Chronic HBV
Unlike NAs, which inhibit viral DNA polymerase, bepirovirsen targets the pregenomic RNA (pgRNA) through antisense hybridization, preventing cccDNA transcription—the root cause of persistent HBsAg expression. In the phase 3 trial (NCT04631246), 353 HBeAg-negative adults with compensated HBV cirrhosis were randomized 2:1 to receive 300 mg subcutaneous bepirovirsen weekly for 24 weeks, with or without tenofovir disoproxil fumarate (TDF). The primary endpoint—HBsAg loss at week 48—was met in 20% of the monotherapy group and 23% of the combination group, compared to 1% in the TDF-only arm.
The mechanism’s novelty lies in its ability to deplete intracellular pgRNA pools, a strategy distinct from direct cccDNA modulation.
“This is the first therapy to demonstrate meaningful HBsAg loss without relying on immune activation,” said Dr. Jordan Feld, a hepatologist at Toronto General Hospital and lead investigator. “The challenge now is proving that these losses are durable and translate to reduced morbidity.”
Phase 3 Efficacy: A Comparative Breakdown
Below, the trial’s key demographic and efficacy metrics, compared to historical NA benchmarks:
| Metric | Bepirovirsen + TDF | Bepirovirsen Monotherapy | TDF Monotherapy (Historical Control) |
|---|---|---|---|
| HBsAg loss at week 48 | 23% | 20% | 1% |
| HBeAg seroconversion | 18% | 15% | 3% |
| Viral load < 20 IU/mL at week 48 | 98% | 95% | 100% |
| Serious adverse events | 8% | 9% | 5% |
Source: NEJM Ahead of Print, 2026. Full study.
Safety Profile: Managing Injection-Related Risks
The most common adverse events (AEs) were injection-site reactions (68%) and pyrexia (42%), consistent with other oligonucleotide therapies like inclisiran. No cases of hepatic decompensation or renal impairment were observed. However, the trial excluded patients with decompensated cirrhosis or HBV/HDV coinfection, limiting generalizability.
“The AE profile is manageable but underscores the need for clinician training in subcutaneous administration,” noted Dr. Anna Lok, a hepatologist at the University of Michigan. “This will be critical for adoption in resource-limited settings where HBV prevalence is highest.”
Funding and Transparency: The Role of Ionis Pharmaceuticals
The study was funded by Ionis Pharmaceuticals, the developer of bepirovirsen, with additional support from the National Institute of Allergy and Infectious Diseases (NIAID). While industry sponsorship is standard in late-stage trials, the lack of independent data monitoring raises questions about potential bias. Trial registry details confirm no conflicts of interest were declared by the lead investigators.
Clinical Triage: Who Needs This Therapy—and Where?
Bepirovirsen’s approval trajectory hinges on two critical questions: Who should receive it? And Where can they access it? For now, the answer lies with specialized hepatology centers equipped to monitor long-term outcomes.
For patients: Those with compensated HBV cirrhosis who have failed or are intolerant to NAs may now have a viable path to functional cure. However, board-certified hepatologists with experience in HBV therapeutics should guide treatment decisions, given the need for close AE monitoring.
For clinicians: Integrating bepirovirsen into practice will require collaboration with pharmaceutical distributors to navigate supply chain logistics, as well as healthcare compliance attorneys to ensure adherence to emerging EMA/FDA guidance on combination therapies.
For researchers: The field now awaits phase 4 data on durability of HBsAg loss. Institutions like the NIAID and WHO will play a pivotal role in designing post-marketing surveillance studies.
The Road Ahead: Combination Therapy as the New Standard?
The phase 3 results suggest that bepirovirsen’s true potential may lie in combination with NAs, mirroring the synergistic approach seen with peginterferon. If confirmed, this could redefine HBV treatment algorithms—moving from viral suppression to cure-oriented regimens. Yet regulatory hurdles remain: The EMA’s Committee for Medicinal Products for Human Use (CHMP) has yet to issue guidance on functional cure endpoints and the FDA’s accelerated approval pathway may require additional biomarkers.
One certainty is that the HBV treatment landscape is evolving. For providers and patients alike, the time to engage with specialized hepatology clinics is now—before the next wave of data reshapes clinical practice.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.